Shots:
- Intellia has reported the first pts dosing in its P-III (MAGNITUDE-2) trial assessing nexiguran ziclumeran (nex-z) for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN); BLA submission is expected in 2028
- Trial will assess nex-z (55mg infusion) vs PBO in ~50 ATTRv-PN pts to evaluate modified neuropathy impairment score & change in serum TTR levels as 1EP
- Trial builds on promising P-I study data showing that a single dose of nex-z lead to rapid & durable reduction in blood TTR levels, with longer-term P-I data for both ATTR polyneuropathy & cardiomyopathy expected by late 2025
Ref: Intellia Therapeutics | Image: Intellia Therapeutics
Related News:- Johnson & Johnson Reports P-IIIb (APEX) Trial Findings of Tremfya for Active Psoriatic Arthritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
